Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 3, 2011, Pages 238-242

  Izumi, K ^a   Mizokami, A ^a   Sugimoto, K ^b   Narimoto, K ^a   Kitagawa, Y ^a   Koh, E ^a   Namiki, M ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

androgen deprivation therapy; bone loss; risedronate

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; DEOXYPYRIDINOLINE; GONADORELIN AGONIST; RISEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLURRED VISION; BONE DENSITY; CONTROLLED STUDY; CONVALESCENCE; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALAISE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SPINE METASTASIS; URINE LEVEL; VERTIGO;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; AMINO ACIDS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LOST TO FOLLOW-UP; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 80054757854     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.10     Document Type: Article

References (27)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
3. Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol 2006; 176: S47-S49 (Pubitemid 44648136)
4. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106: 1708-1714
5. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-254 (Pubitemid 46684481)
6. Holzbeierlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003; 2: 147-152 (Pubitemid 38044661)
7. Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009; 73: 1342-1346
8. Labrie F, Cusan L, Gomez JL, Belanger A, Candas B. Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 1999; 3: 217-226
9. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujisawa S, Shiraki M et al. Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331-337
10. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186
11. Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003; 44: 661-665 (Pubitemid 37542923)
12. Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101: 541-549 (Pubitemid 38970605)
13. Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist 2004; 9 (Suppl 4): 38-47 (Pubitemid 39363167)
14. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955
15. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012 (Pubitemid 36576705)
16. Saad F, Abrahamsson PA, Miller K. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int 2009; 104: 1573-1579
17. Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007; 14: 1071-1075 (Pubitemid 350151272)
18. Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010; 106: 1473-1476
19. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008; 26: 4426-4434
20. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63: 534-546
21. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424 (Pubitemid 351650576)
22. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006; 63: 419-430 (Pubitemid 43348392)
23. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-1558 (Pubitemid 47500128)
24. Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000; 59: 765-772
25. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195-202 (Pubitemid 38142449)
26. Delmas PD, Benhamou CL, Man Z, TlustochowiczW, Matzkin E, Eusebio R et al. Monthly dosing of 75mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19: 1039-1045
27. Moro-Alvarez MJ, D́az-Curiel M. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging 2008; 3: 227-232 (Pubitemid 352037862)